

Regulatory T cells Tregs in antitumor response



Mieloid DC





Plasmocytoid DC





	Phenotype	pDC/IPC	Monocytes	CD11c ⁺ immature DC			
	Myeloid marker						
Uuman	CD11b	_	+	+			
Human	CD11c	_	+	+			
DC	CD13	—	+	+			
	CD14	—	+	—			
	CD33	_	+	+			
	Lymphoid marker						
	Pre-Ta	+	_	_			
	Ig1-like 14.1	+	_	_			
	Spi-B	+	_	_			
	Pattern recognition receptors						
	TLR1	+	++	+			
	TLR2		++	+			
	TLR3	_	_	++			
	TLR4	_	++	+			
	TLR5	_	+	+			
	TLR6	+	+	+			
	TLR7	++	_	—			
	TLR8	—	++	++			
	TLR9	++	—	—			
	TLR10	+	_	+			
	Mannose R	_	+/-	+/-			
	BDCA2	+	—	—			
	CD1a, b, c, d	—	+/-	+/-			
Other differentially expressed antigens							
	CD4	++	+	+			
	CD45RA	+	—	—			
	CD45RO	_	+	+			
	IL-3R	+++	+	+			
	GM-CSFR	+	++	++			
	Function						
	IFN- α/β production	++++	+	+			
	IL-12 production	—	++	++			
	phagocytosis	—	++	++			

DC in immunity









DC in tolerance

iDC


Ε

C

Ε

Lack of immunogenic factors

Tolerogenic factors TGF-beta, IL-10 Tregs



Types of effector T cell	CD8 cytotoxic T cells	CD4 T _H 1 cells	CD4 T _H 2 cells	CD4 T _H 17 cells	CD4 regulatory T cells (various types)
		T _H 1	T _H 2		Treg
Main functions in adaptive immune response	Kill virus-infected cells	Activate infected macrophages Provide help to B cells for antibody production	Provide help to B cells for antibody production, especially switching to IgE	Enhance neutrophil response	Suppress T-cell responses
Pathogens targeted	Viruses (e.g. influenza, rabies, vaccinia) Some intracellular bacteria	Microbes that persist in macrophage vesicles (e.g. mycobacteria, <i>Listeria,</i> <i>Leishmania</i> <i>donovani,</i> <i>Pneumocystis</i> <i>carinii</i>) Extracellular bacteria	Helminth parasites	Extracellular bacteria (e.g. Salmonella enterica)	

Figure 8-1 Immunobiology, 7ed. (© Garland Science 2008)





Figure 8-29 Immunobiology, 7ed. (© Garland Science 2008)


High-affinity IL-2 receptors are 3-chain structures



Tregs-few facts

- Tregs are a distinct lymphocyte lineage endowed with regulatory properties
- IL2 is crucial for Tregs homeostasis and costimulatory molecules CD80 and CD40 are required for peripheral Tregs maintenance
- Naturally occurring Tregs are generated in thymus
- Induced Tregs probably can be generated in the periphery from naïve T cells
- Tregs account for 5-10% of the circulating CD4 T cell population


Phenotype of Tregs



Transcription factor forkhead box P3 (Foxp3)


- A disease-causative gene in Scurfy mice, which spontaneously develop severe autoimmunity/inflammation
- The key controlling factor in a development and function of natural Tregs
- Foxp3 up-regulates Tregs-associated molecules (CD25, CTLA-4, GITR) and downregulates IL2, IL4 and Intγ
- Expression of Foxp3 in naïve T cells is sufficient to convert them into phenotypically and functionally Treg-like cells

Tregs inhibit:




Treg cell depletion induces:


- Polyclonal T cell activation
- Systemic DC expansion and maturation





Critical role of CTLA-4 in Treg-mediated supression

- Tregs (Foxp3+CD25+CD4+) constitutively express high levels of CTLA-4, Foxp3 upregulates CTLA-4 expression
- Blockade of CTLA-4 produces organ-specific autoimmunity (IBD, diabetes)
- Mice lacking CTLA-4 in Treg cells, similarily to Foxp3-deficient mice develop lymphoproliferation, autoimmune diseases and IgE hyperproduction










Tumors perturb Tregs homeostasis

- During tumor progression, the initial immunity is finally subverted by CD4 T cell-mediated immune suppression, suggesting that effector and suppressor subpopulations might be functionally predominant at different stages of tumor progression
- Suppression of immunity occurs when Tregs outnumber effector T cells
- The increase in Tregs is not unlimited and does not exceed 50% of the CD4 population
- Tregs accumulation and compartmentalization can vary among different cancers

Tregs in tumor immunity



Tregs functional inactivation

